VIDEO: Review finds no difference in anti-VEGF agents used for diabetic retinopathy

SAN FRANCISCO — At the American Society of Retina Specialists meeting here, Arshad Khanani, MD, discusses a review of the many clinical trials examining the efficacy of anti-VEGF agents in treating diabetic retinopathy, such as RISE/RIDE, VIVID/VISTA, Protocol I and Protocol S. The review found overall one-third of patients showed a two-step improvement in their diabetic retinopathy severity score, regardless of the anti-VEGF agent used.